An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context

Recruiting now

Conditions studied: Castleman Disease

In brief

The study is a pilot, observational, retrospective, and (italian) multicenter study. The study will involve the collection of patient data from medical records for patients with Multicentric Castelman Disease Relapsed/Refractory who received treatment with at least one dose of siltuximab, as part of standard of care in a real-life context, from July 2016 till April 2022 in 31selected italian centres.

Key facts

Study ID

NCT06720870

Run by

IRCCS Azienda Ospedaliero-Universitaria di Bologna

People needed

65

Starts

2023-03-01

Expected to finish

2025-01-01

Last updated by the study team

2024-12-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed diagnosis of R/R MCD HIV and HHV-8 negative patients who underwent siltuximab in a real-life context from July 2016 till April 2022.
• Age ≥ 18 yearsatenrollment
• Signature of written informed consent (where applicable)

You may not qualify if…

• R/R MCD patients who underwent siltuximab in a clinical trial context

Where it is running

• IRCCS Azienda Ospedaliero - Universitaria di Bologna — Bologna, Bologna, Italy (enrolling)
• Azienda Ospedaliera Sant'Anna e San Sebastiano — Caserta, Caserta, Italy (enrolling)
• Policlinico di Bari - Azienda Ospedaliero Universitaria Consorziale Policlinico — Bari, Italy (enrolling)
• Azienda Ospedaliera Universitaria Arcispedale Sant'Anna — Ferrara, Italy (enrolling)
• Azienda Ospedaliero Universitaria Careggi — Florence, Italy (enrolling)
• Irccs Ospedale San Raffaele — Milan, Italy (enrolling)
• Azienda Ospedaliero-Universitaria "Maggiore della Carità" — Novara, Italy (enrolling)
• Azienda Ospedaliera Di Padova — Padova, Italy (enrolling)
• Fondazione IRCCS Policlinico San Matteo — Pavia, Italy (enrolling)
• Azienda Ospedaliera Universitaria Senese — Siena, Italy (enrolling)
• Azienda ULSS 2 Marca Trevigiana - UOC Medicina Interna 1 Centro di Riferimento per le Malattie Rare del Sistema Immunitario e dell'Apparato Respiratorio — Treviso, Italy (enrolling)
• Azienda Ulss 2 Marca Trevigiana- Ospedale Di Treviso — Treviso, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.